Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares MSCI Japan ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Japan ETF trades at $91.85, while Heron Therapeutics Inc trades at $0.49 (market cap $84.50M). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EWJHRTX
Sector
Broad Market / FactorHealth
52-Week High
$96.97$2.02
52-Week Low
$71.81$0.39
Market Cap
$84.50M
Enterprise Value
$182.40M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ, the iShares MSCI Japan ETF, trades at $91.92, down 2.1% on the day, with a bullish technical signal from moving averages but neutral oscillators. The fund provides exposure to Japanese equities amid a weakening yen, with news highlighting potential currency intervention by Japanese authorities and domestic investment pushes. Recent performance reflects Nikkei 225 volatility, trading near all-time highs before recent pullbacks.

Outlook hinges on yen stability and Japanese economic policies, with opportunities in hedged alternatives to mitigate currency risk. Risks include FX volatility, geopolitical tensions, and Japan's debt burden. Analyst sentiment is mixed, focusing on currency dynamics and equity market resilience.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, up 13.93% today, showing volatile momentum amid mixed technical signals. The company maintains strong gross margins of 71.12% but struggles with profitability, posting a net loss of $20.20 million in 2025. Recent Q1 2026 earnings missed expectations with a $0.04 loss per share, though management reaffirmed full-year guidance. Analyst consensus remains overwhelmingly bullish with 94.74% buy ratings, contrasting with a recent Zacks Strong Sell designation.

HRTX presents a high-risk opportunity with significant analyst support but persistent financial challenges. The bullish sentiment stems from potential patent developments and commercial execution, while risks include ongoing losses, competitive pressures, and the discrepancy between analyst optimism and recent negative ratings. The stock's current valuation at 0.49x sales appears reasonable if the company can achieve profitability.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX